News from Thursday, June 19, 2025
Articles
Most Favored Nation Has No Place in U.S. Healthcare
(6/17, John “CZ” Czwartacki, RealClearHealth) comments “...MFN would inexplicably link our medicine to failing foreign countries. This artificial price fixing will force manufacturers to pull back investment in research and development as they face uncertainty about new product discoveries...Moreover, many of these countries impose prices that are determined using discriminatory valuation tools. These pricing mechanisms, like the quality-adjusted life year (QALY), devalue and de-prioritize care for the sickest patients. They keep prices lower by just selling to patients deemed more valuable.” Full
UK: Human Data Sciences Launches Breakthrough in Comparative Outcomes Research
(6/19, Oliver Johnson, MedTech Insights) reports “Human Data Sciences (HDS), the UK-based MedTech company behind the real-world data analytics platform Livingstone, has launched a landmark update to the platform that enables researchers to conduct comparative outcomes studies across multiple endpoints simultaneously for the first time in the industry.” Full
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla
(6/19, Neena Brizmohun, Pink Sheet) reports “...Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.” Subscription Required
Press Releases
NUCDF Launches National Project to Advance Urea Cycle Disorder Research
(6/19, National Urea Cycle Disorders Foundation Press Release) “The National Urea Cycle Disorders Foundation (NUCDF), the leading patient advocacy group for people affected by urea cycle disorders (UCDs), today announced the launch of a two-year national project to establish the multistakeholder NUCDF Partner Network and develop a roadmap for future research in these rare disorders. The project is funded through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI).” Full
Final Draft Guidance Finds Benefits of 2 Alzheimer’s Treatments Remain Too Small to Justify the Additional Cost to the NHS
(6/19, NICE Press Release) “The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.” Full
Journals
Semaglutide versus Other GLP-1 Receptor Agonists in Patients with MASLD
Chia-Chih Kuo, et al.
June 19, 2025, Hepatology Communications
Moderators of Antidepressant Augmentation Versus Switch in the OPTIMUM Randomised Controlled Trial
Helena K. Kim, et al.
June 19, 2025, The British Journal of Psychiatry
Events
Webinar: NPC's John O'Brien to Join AJMC Webinar on Navigating 2025 Drug Pricing Policies
June 26, 2025
12:00PM EST